Mr Martin joined Verona in 2020 and is our Chief Commercial Officer.
Mr Martin has almost 20 years of commercial expertise spanning sales, marketing and business development. From March 2018 until May 2020, he served as Executive Director of Marketing at SK Life Science, a subsidiary of SK Biopharmaceutical, which is focused on developing novel therapeutics for CNS conditions. Mr Martin was instrumental in developing the commercial and marketing strategy and the framework for launching SK Life Science’s first commercial product, XCOPRI® (cenobamate tablets). In addition to his responsibilities in marketing, he served on the pre-IPO team. From 2016 until its acquisition by Melinta Therapeutics in 2017, Mr Martin was Head of Marketing at Cempra where he led the development and launch strategy for the company’s first product. Prior to Cempra, he was at Salix Pharmaceuticals for 10 years in roles of increasing responsibility and led the Xifaxan® marketing team during the company’s acquisition by Valeant Pharmaceuticals. Mr Martin received a Bachelor of Science in Financial Management from Clemson University.
